| Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 | Dec'15 | Sep'15 | Jun'15 | Mar'15 | Dec'14 | Sep'14 | Jun'14 | Mar'14 | Dec'13 | Sep'13 | Jun'13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flows From Operating Activities: | ||||||||||||||||||||||||||
Net loss | ||||||||||||||||||||||||||
- | -1,117,040 | -1,251,265 | - | - | -1,139,275 | -763,154 | - | - | - | -407,787 | -359,235 | -375,366 | -322,482 | -494,183 | -417,719 | -328,784 | -390,308 | -402,826 | -535,939 | -158,766 | -355,885 | -269,250 | -162,126 | -340,196 | -22,133 | -61,778 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||||||||||||||
Depreciation and Amortization | ||||||||||||||||||||||||||
19,212 | 17,290 | 11,048 | 11,483 | 12,268 | 2,880 | 6,776 | 6,789 | 7,436 | 9,962 | 5,069 | 4,804 | 4,592 | 6,120 | 4,917 | 4,956 | 3,595 | 4,776 | 4,077 | 2,020 | 3,709 | 423 | 1,404 | 2,869 | 1,141 | 368 | 721 |
Stock Based Compensation | ||||||||||||||||||||||||||
40,000 | 115,410 | 162,254 | 245,943 | 69,167 | 114,500 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Other Cost of Services | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 316,157 | -715 | -96,579 |
Changes in assets and liabilities: | ||||||||||||||||||||||||||
Increase (Decrease) in Receivables | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15,194 |
Prepaid expenses and other receivables | ||||||||||||||||||||||||||
56,306 | -65,891 | -197,131 | 219,149 | 246,234 | -129,167 | 119,909 | 75,454 | 46,058 | 4,333 | 13,014 | -16,246 | 17,584 | -52,132 | -34,573 | -130,503 | 14,942 | -99,746 | -9,085 | 386,084 | -8,877 | -13,417 | 44,015 | - | - | - | - |
Inventory | ||||||||||||||||||||||||||
15,766 | 171,842 | -1,471 | -37,396 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts payable and other liabilities | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 84,453 | -41,613 | 35,064 | - | -90,825 | 33,079 | 106,781 | - | - | - | - |
Prepayment to related party for clinical trials | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 498,918 | -19,912 | -51,753 | -177,794 | -494,491 | -21,072 | -45,569 | 561,132 | - | - | - | - |
Accounts payable | ||||||||||||||||||||||||||
-37,751 | 42,124 | 16,886 | -57,168 | 149,931 | -87,115 | 92,470 | -15,892 | -87,756 | 54,452 | 17,949 | 23,106 | 29,657 | -92,117 | 41,876 | - | - | - | - | - | - | - | - | - | - | - | - |
Liability due to related party | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | 299,389 | -317,352 | 95,617 | - | 423,237 | -193,419 | 193,419 | - | - | - | - | - | - | - | - | - | - | - | - |
Other liabilities and accrued expenses | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | 4,076 | 24,947 | 14,200 | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Liability due to related party | ||||||||||||||||||||||||||
-369,016 | -35,417 | 135,950 | 337,340 | 274,946 | -114,297 | 199,193 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Other liabilities and accrued expenses | ||||||||||||||||||||||||||
163,388 | -89,917 | 37,309 | 65,812 | -180,435 | -16,859 | 152,976 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accrued interest receivable | ||||||||||||||||||||||||||
0 | 0 | 0 | 141,286 | -69,547 | 7,829 | -8,809 | -14,937 | -4,209 | -54,295 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Advances from related party | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - | - | - | - | - |
Net cash used in operating activities | ||||||||||||||||||||||||||
-701,246 | -1,170,559 | -692,158 | -1,242,586 | -776,699 | -1,101,210 | -440,457 | -875,873 | -293,488 | -679,650 | -287,966 | -488,200 | -205,674 | -279,556 | -219,398 | -521,147 | -235,766 | -275,646 | -176,806 | -187,321 | -215,933 | -263,397 | -766,212 | 1,709,966 | -41,884 | 9,578 | -172,830 |
Cash Flows from Investing Activities: | ||||||||||||||||||||||||||
Purchase of intangible assets | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 34,769 | - | - | - | - | - | - | - | - | - | - | - | - |
Decrease in restricted cash | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | -94,917 | 9,455 | - | - | - | - |
Capitalized patent costs | ||||||||||||||||||||||||||
22,260 | 17,417 | 10,893 | 6,487 | 6,778 | -2,799 | 9,865 | 15,528 | 4,487 | 12,887 | 12,358 | - | - | - | - | 27,863 | -525 | 2,248 | 48,611 | 69,564 | -15,498 | 21,306 | 1,373 | - | - | - | - |
Purchase of property and equipment | ||||||||||||||||||||||||||
28,899 | 57,025 | 76,691 | 16,450 | 43,216 | 0 | 0 | - | - | - | - | - | - | - | - | 3,761 | -3,960 | 4,799 | 4,767 | -41,765 | 50,864 | 6,358 | 0 | - | - | - | - |
Fixed rate savings account | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | -38,986 | -1,316,029 | 7,990 | -647,450 | - | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Purchase of Intellectual Property | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8,848 |
Net cash (used in) provided by investing activities | ||||||||||||||||||||||||||
-51,159 | -74,442 | -87,584 | -8,235 | 3,095,156 | 1,326,799 | -9,865 | 23,458 | 1,311,542 | -20,877 | 635,092 | -6,241,818 | -1,865 | -27,637 | -34,769 | -31,624 | 4,485 | -7,047 | -53,378 | -27,799 | -35,366 | 67,253 | -10,828 | -86,933 | -977 | -1,131 | -8,848 |
Cash Flows from Financing Activities: | ||||||||||||||||||||||||||
Costs incurred in relation to ATM equity financing | ||||||||||||||||||||||||||
0 | 0 | 9,575 | - | 121,880 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross proceeds from issuance of common stock in relation to ATM financing | ||||||||||||||||||||||||||
0 | -1 | 152,493 | 0 | 455,105 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross proceeds from warrant exercise/unit option purchase | ||||||||||||||||||||||||||
0 | 0 | 26,000 | 63,711 | 600 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net cash provided by financing activities | ||||||||||||||||||||||||||
-28,207 | -1 | 168,918 | -85,791 | 2,135,146 | 500 | 0 | - | - | - | - | - | - | - | - | 59,717 | 9,985,044 | 254,673 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
Net (decrease) increase in cash | ||||||||||||||||||||||||||
-780,612 | -1,245,002 | -610,824 | -1,336,612 | 4,453,603 | 226,089 | -450,322 | -852,415 | 1,018,054 | -700,527 | 347,126 | -6,730,018 | -207,539 | -307,193 | -254,167 | -493,054 | 9,753,763 | -28,020 | -230,184 | -215,120 | -251,299 | -196,144 | -777,040 | 1,888,515 | -42,861 | 8,447 | -181,678 |
Effect of exchange rate changes on cash | ||||||||||||||||||||||||||
77,160 | -52,424 | -61,299 | 36,615 | 60,910 | -19,933 | -52,021 | 10,134 | 49,023 | 13,623 | 25,958 | 48,023 | -517,389 | 131,326 | -655,649 | 45,723 | -2,287 | 2,009 | 1,266 | -43,739 | -42,395 | -8,248 | 15,593 | -22,200 | 21,427 | 2,371 | -1,365 |
Supplemental disclosure of non-cash financing activities: | ||||||||||||||||||||||||||
Conversion of Series A preferred stock to common stock | ||||||||||||||||||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 137,324 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Prepayment of equity compensation | ||||||||||||||||||||||||||
- | -17,319 | 103,034 | - | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |